J.P. Morgan said it believes Structure has some advantages over other companies trying to enter the oral GLP-1 market, including a small molecule formation for its product and a “slight” time ...

有“反疫苗先锋”之称的Kennedy强烈反对GLP-1药物，认为它们是解决肥胖危机的错误方法。周五，“减肥双雄”礼来和诺和诺德的股价受此影响分别下跌了4.93%和3.4%，其他致力于开发减肥药物的公司股票也遭受重创。

The uptake of GLP-1 has surged since 2022, mainly in US. Read our takeaways from the UBS Evidence Lab survey on key trends in GLP-1 consumer behaviour GLP-1s, also known as glucagon-like peptide 1, ...